Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 35 (1) , 111-116
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 41 references indexed in Scilit:
- Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancerJournal of Clinical Investigation, 2011
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- PPARγ agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cellsPharmacological Research, 2010
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- θ Isoform of Protein Kinase C Alters Barrier Function in Intestinal Epithelium through Modulation of Distinct Claudin Isotypes: A Novel Mechanism for Regulation of PermeabilityThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Recognition and processing of cisplatin- and oxaliplatin-DNA adductsCritical Reviews in Oncology/Hematology, 2005
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- cDNA Cloning and Functional Expression of a Novel Rat Kidney Organic Cation Transporter, OCT2Biochemical and Biophysical Research Communications, 1996
- The Protein Kinase C Inhibitor, Bisindolylmaleimide, Inhibits the TPA-Induced But Not the TNF-Induced Increase in LLC-PK1 Transepithelial PermeabilityBiochemical and Biophysical Research Communications, 1995